A study published in the June issue of Hypertension demonstrates that the leading angiotensin receptor blocker Novartis Diovan (valsartan) in combination with the diuretic hydrochlorothiazide improves artery elasticity, a sign of artery aging, in patients with type 2 diabetes, high blood pressure and kidney disease compared to those taking another widely-used blood pressure medicine, amlodipine.
Diovan/HCT demonstrated significantly superior benefits on artery elasticity compared to amlodipine, even though both treatment regimens had a similar effect in reducing blood pressure, noted the Swiss drug major, adding that this is the first report of an improvement in artery elasticity with an ARB in this patient population. The aging process is associated with a gradual loss of elasticity in the arteries, but this is prematurely accelerated in people with diabetes and/or high blood pressure. Patients with less elastic arteries are at increased risk of stroke and heart attack. The study demonstrated that Diovan/HCT, the world's best-selling branded high blood pressure medication, improved the elasticity of arteries in people with high blood pressure, type 2 diabetes and kidney disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze